We’re excited to take part in this year’s EuroSpine Annual Meeting (October 22–24) and to share new updates on VCFix combined with short-level posterior fixation for treatment of traumatic burst fractures.
On October 23, our R&D Engineer Jet Moolenaar will present cadaveric functionality results from ex vivo testing. The study demonstrates how hashtag#VCFix, when combined with monosegmental posterior fixation, enhances vertebral restoration in burst fractures while preserving adjacent segment mobility.
We look forward to exchanging insights on the hashtag#VCFix Spinal System and learning from the latest developments in the spine field.
📢 Interested in a conversation or demo? Reach out to Jet Moolenaar! See you in Copenhagen!
About Amber Implants
Amber Implants is now a commercial stage company, preparing for its US launch in 2026. Supported by strong worldwide patent protection and a growing product pipeline, the Company is on track to capture a significant share of the global €2 billion+ vertebral compression fracture market by 2029. FDA clearance of the VCFix® Spinal System not only accelerates adoption and revenue growth but also serves as a gateway for entry into additional global markets where FDA approval is recognized.
